ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent recommendations highlight treatment-free remission (TFR) as a new significant goal of CML management, with sustained deep molecular response (DMR; BCR-ABL1 < 0.01% IS) as a prerequisite for a TKI discontinuation attempt [38].